PRPO Stock Overview
A healthcare solutions company, provides diagnostic products, reagents, and services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Precipio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.27 |
| 52 Week High | US$7.30 |
| 52 Week Low | US$4.31 |
| Beta | 1.41 |
| 1 Month Change | -10.82% |
| 3 Month Change | -21.93% |
| 1 Year Change | -18.92% |
| 3 Year Change | -85.20% |
| 5 Year Change | -87.08% |
| Change since IPO | -99.80% |
Recent News & Updates
Investors Aren't Entirely Convinced By Precipio, Inc.'s (NASDAQ:PRPO) Revenues
Dec 20
Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price Boost
Aug 21Recent updates
Investors Aren't Entirely Convinced By Precipio, Inc.'s (NASDAQ:PRPO) Revenues
Dec 20Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price Boost
Aug 21Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet
Jun 07Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)
Mar 29Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An Opportunity
Aug 29Precipio to distribute HemeScreen through Fisher Healthcare channel
Jul 20Precipio terminates its equity line with Lincoln Park
Jun 15We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation
Jun 12Precipio shares surge on HemeScreen Anemia Panel launch
Jun 08Precipio shares surge on launching hemescreen panel for Acute Myeloid Leukemia
May 10Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke
May 05Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform
May 03Shareholder Returns
| PRPO | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -9.5% | -4.1% | -2.4% |
| 1Y | -18.9% | -10.2% | 23.4% |
Return vs Industry: PRPO underperformed the US Healthcare industry which returned -10.2% over the past year.
Return vs Market: PRPO underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| PRPO volatility | |
|---|---|
| PRPO Average Weekly Movement | 5.4% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRPO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PRPO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 54 | Ilan Danieli | www.precipiodx.com |
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.
Precipio, Inc. Fundamentals Summary
| PRPO fundamental statistics | |
|---|---|
| Market cap | US$7.81m |
| Earnings (TTM) | -US$3.00m |
| Revenue (TTM) | US$17.41m |
0.4x
P/S Ratio-2.6x
P/E RatioIs PRPO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRPO income statement (TTM) | |
|---|---|
| Revenue | US$17.41m |
| Cost of Revenue | US$10.49m |
| Gross Profit | US$6.93m |
| Other Expenses | US$9.93m |
| Earnings | -US$3.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.02 |
| Gross Margin | 39.78% |
| Net Profit Margin | -17.23% |
| Debt/Equity Ratio | 4.4% |
How did PRPO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 13:02 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Precipio, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| Jason McCarthy | Maxim Group |